Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hypoxia and Tumor Angiogenesis in the Era of Hepatocellular Carcinoma Transarterial Loco-Regional Treatments
Mario Petrillo, Francesca Patella, Filippo Pesapane, et al.
Future Oncology (2018) Vol. 14, Iss. 28, pp. 2957-2967
Closed Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Josep M. Llovet, Thierry de Baère, Laura Kulik, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 5, pp. 293-313
Closed Access | Times Cited: 701
Hypoxia blocks ferroptosis of hepatocellular carcinoma via suppression of METTL14 triggered YTHDF2‐dependent silencing of SLC7A11
Zhuoyang Fan, Guowei Yang, Wei Zhang, et al.
Journal of Cellular and Molecular Medicine (2021) Vol. 25, Iss. 21, pp. 10197-10212
Open Access | Times Cited: 123
Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer
Anubhab Mukherjee, Vijay Sagar Madamsetty, Manash K. Paul, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 2, pp. 455-455
Open Access | Times Cited: 89
Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: a comprehensive review on targeting and recent advances
Khaled Y. Mahmoud, Shady A. Swidan, Mohamed A. El-Nabarawi, et al.
Journal of Nanobiotechnology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 66
A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment
Jen‐Shin Song, Chih-Chun Chang, Chien-Huang Wu, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 13
Open Access | Times Cited: 62
Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma
Xiaomeng Dai, Yixuan Guo, Yan Hu, et al.
Theranostics (2021) Vol. 11, Iss. 7, pp. 3489-3501
Open Access | Times Cited: 58
HIF-2α-targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma
Minjiang Chen, Gaofeng Shu, Xiuling Lv, et al.
Biomaterials (2022) Vol. 284, pp. 121512-121512
Closed Access | Times Cited: 41
Sustained release hypoxia-activated prodrug-loaded BSA nanoparticles enhance transarterial chemoembolization against hepatocellular carcinoma
Ying-Hong Hao, Wenzhi Zhu, Jie Li, et al.
Journal of Controlled Release (2024) Vol. 372, pp. 155-167
Closed Access | Times Cited: 9
A Case of DEB-TACE Combined with Anlotinib for Treatment of Liver Metastasis from Retroperitoneal Leiomyosarcoma
Huiying Cui, Qiang Xu, Zhezhu Han, et al.
Journal of Hepatocellular Carcinoma (2025) Vol. Volume 12, pp. 459-465
Open Access | Times Cited: 1
Transarterial chemoembolization plus a PD‐1 inhibitor with or without lenvatinib for intermediate‐stage hepatocellular carcinoma
Yan‐Jun Xiang, Kang Wang, Hongming Yu, et al.
Hepatology Research (2022) Vol. 52, Iss. 8, pp. 721-729
Closed Access | Times Cited: 33
Recent Progress in Advanced Hydrogel‐Based Embolic Agents: From Rational Design Strategies to Improved Endovascular Embolization
Xiaohong Li, Muhammad Wajid Ullah, Basen Li, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 17
Closed Access | Times Cited: 21
Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study
Kang Wang, Hongfei Zhu, Hongming Yu, et al.
Journal of Oncology (2023) Vol. 2023, pp. 1-8
Open Access | Times Cited: 17
Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies
Elisa Pinto, Filippo Pelizzaro, Fabio Farinati, et al.
Medicina (2023) Vol. 59, Iss. 6, pp. 1115-1115
Open Access | Times Cited: 17
Autophagy-Targeted Calcium Phosphate Nanoparticles Enable Transarterial Chemoembolization for Enhanced Cancer Therapy
Gang Yuan, Yanneng Xu, Xiaopeng Bai, et al.
ACS Applied Materials & Interfaces (2023) Vol. 15, Iss. 9, pp. 11431-11443
Closed Access | Times Cited: 16
Jiedu Recipe, a compound Chinese herbal medicine, inhibits cancer stemness in hepatocellular carcinoma via Wnt/β-catenin pathway under hypoxia
Bing-jie Guo, Yi Ruan, Yajing Wang, et al.
Journal of Integrative Medicine (2023) Vol. 21, Iss. 5, pp. 474-486
Closed Access | Times Cited: 16
Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate‐stage Hepatocellular Carcinoma: A Multicenter Retrospective Study
Yitao Zheng, Yan‐Jun Xiang, Hongqi Shi, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 1079-1093
Open Access | Times Cited: 6
Intermittent hypoxia alleviates increased VEGF and pro‑angiogenic potential in liver cancer cells
Gang Dong, Xiahui Lin, Hua‐Hua Liu, et al.
Oncology Letters (2019)
Open Access | Times Cited: 39
Multifunctional nanoplatforms application in the transcatheter chemoembolization against hepatocellular carcinoma
Gang Yuan, Zhiyin Liu, Weiming Wang, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 13
Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
Haohao Lu, Bin Liang, Xiangwen Xia, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study
Nan Jiang, Bin‐Yan Zhong, Jintao Huang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
HIF-1α and VEGF as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolization
Elisa Pinto, Filippo Pelizzaro, Romilda Cardin, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 5, pp. 872-879
Open Access | Times Cited: 10
Oleanolic acid inhibits hypoxic tumor-derived exosomes-induced premetastatic niche formation in hepatocellular carcinoma by targeting ERK1/2-NFκB signaling
Wentao Jia, Shufang Liang, Mingming Jin, et al.
Phytomedicine (2023) Vol. 126, pp. 155208-155208
Closed Access | Times Cited: 10
Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study
Chengxiang Guo, Weibo Du, Yiwen Chen, et al.
Cancer Medicine (2025) Vol. 14, Iss. 3
Open Access
Transarterial Chemoembolization with BioPearls for the Treatment of Hepatocellular Carcinoma: A Preliminary Experience
Roberto Iezzi, Alessandro Posa, Irene Bargellini, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 307-307
Open Access
The solid tumor microenvironment and related targeting strategies: a concise review
Yingliang Wang, Huimin Zhou, Shuguang Ju, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Page 1 - Next Page

Scroll to top